242 related articles for article (PubMed ID: 28473136)
1. Ranolazine After Incomplete Percutaneous Coronary Revascularization in Patients With Versus Without Diabetes Mellitus: RIVER-PCI Trial.
Fanaroff AC; James SK; Weisz G; Prather K; Anstrom KJ; Mark DB; Ben-Yehuda O; Alexander KP; Stone GW; Ohman EM
J Am Coll Cardiol; 2017 May; 69(18):2304-2313. PubMed ID: 28473136
[TBL] [Abstract][Full Text] [Related]
2. Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization: Results From the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial.
Alexander KP; Weisz G; Prather K; James S; Mark DB; Anstrom KJ; Davidson-Ray L; Witkowski A; Mulkay AJ; Osmukhina A; Farzaneh-Far R; Ben-Yehuda O; Stone GW; Ohman EM
Circulation; 2016 Jan; 133(1):39-47. PubMed ID: 26555329
[TBL] [Abstract][Full Text] [Related]
3. Utility of ranolazine in chronic stable angina patients.
Patel PD; Arora RR
Vasc Health Risk Manag; 2008; 4(4):819-24. PubMed ID: 19065998
[TBL] [Abstract][Full Text] [Related]
4. Effects of Ranolazine in Patients With Chronic Angina in Patients With and Without Percutaneous Coronary Intervention for Acute Coronary Syndrome: Observations From the MERLIN-TIMI 36 Trial.
Gutierrez JA; Karwatowska-Prokopczuk E; Murphy SA; Belardinelli L; Farzaneh-Far R; Walker G; Morrow DA; Scirica BM
Clin Cardiol; 2015 Aug; 38(8):469-75. PubMed ID: 26059896
[TBL] [Abstract][Full Text] [Related]
5. Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial.
Weisz G; Généreux P; Iñiguez A; Zurakowski A; Shechter M; Alexander KP; Dressler O; Osmukhina A; James S; Ohman EM; Ben-Yehuda O; Farzaneh-Far R; Stone GW;
Lancet; 2016 Jan; 387(10014):136-45. PubMed ID: 26474810
[TBL] [Abstract][Full Text] [Related]
6. Use of ranolazine in patients with incomplete revascularization after percutaneous coronary intervention: design and rationale of the Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (RIVER-PCI) trial.
Weisz G; Farzaneh-Far R; Ben-Yehuda O; Debruyne B; Montalescot G; Lerman A; Mahmud E; Alexander KP; Ohman EM; White HD; Olmsted A; Walker GA; Stone GW
Am Heart J; 2013 Dec; 166(6):953-959.e3. PubMed ID: 24268208
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial.
Morrow DA; Scirica BM; Chaitman BR; McGuire DK; Murphy SA; Karwatowska-Prokopczuk E; McCabe CH; Braunwald E;
Circulation; 2009 Apr; 119(15):2032-9. PubMed ID: 19349325
[TBL] [Abstract][Full Text] [Related]
8. Residual Angina After Elective Percutaneous Coronary Intervention in Patients With Diabetes Mellitus.
Grodzinsky A; Kosiborod M; Tang F; Jones PG; McGuire DK; Spertus JA; Beltrame JF; Jang JS; Goyal A; Butala NM; Yeh RW; Arnold SV
Circ Cardiovasc Qual Outcomes; 2017 Sep; 10(9):. PubMed ID: 28904076
[TBL] [Abstract][Full Text] [Related]
9. Physical Activity After Percutaneous Coronary Intervention for Chronic Total Occlusion and Its Association With Health Status.
Peri-Okonny PA; Spertus JA; Grantham JA; Gosch K; Kirtane A; Sapontis J; Lombardi W; Karmpaliotis D; Moses J; Nicholson W; Salisbury AC
J Am Heart Assoc; 2019 Apr; 8(7):e011629. PubMed ID: 30922149
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina).
Kosiborod M; Arnold SV; Spertus JA; McGuire DK; Li Y; Yue P; Ben-Yehuda O; Katz A; Jones PG; Olmsted A; Belardinelli L; Chaitman BR
J Am Coll Cardiol; 2013 May; 61(20):2038-45. PubMed ID: 23500237
[TBL] [Abstract][Full Text] [Related]
11. Ranolazine for the treatment of chronic stable angina: a cost-effectiveness analysis from the UK perspective.
Coleman CI; Freemantle N; Kohn CG
BMJ Open; 2015 Nov; 5(11):e008861. PubMed ID: 26546142
[TBL] [Abstract][Full Text] [Related]
12. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.
Chaitman BR; Pepine CJ; Parker JO; Skopal J; Chumakova G; Kuch J; Wang W; Skettino SL; Wolff AA;
JAMA; 2004 Jan; 291(3):309-16. PubMed ID: 14734593
[TBL] [Abstract][Full Text] [Related]
13. Comparative Effectiveness of Ranolazine Versus Traditional Therapies in Chronic Stable Angina Pectoris and Concomitant Diabetes Mellitus and Impact on Health Care Resource Utilization and Cardiac Interventions.
Page RL; Ghushchyan V; Read RA; Hartsfield CL; Koch BR; Nair KV
Am J Cardiol; 2015 Nov; 116(9):1321-8. PubMed ID: 26358510
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina according to baseline hemoglobin A1c.
Arnold SV; McGuire DK; Spertus JA; Li Y; Yue P; Ben-Yehuda O; Belardinelli L; Jones PG; Olmsted A; Chaitman BR; Kosiborod M
Am Heart J; 2014 Oct; 168(4):457-465.e2. PubMed ID: 25262254
[TBL] [Abstract][Full Text] [Related]
15. Clinical and Economic Outcomes of Ranolazine Versus Conventional Antianginals Users Among Veterans With Chronic Stable Angina Pectoris.
Bress AP; Dodson JA; King JB; Sauer BC; Reese T; Crook J; Radwanski P; Knippenberg K; Greene T; Nelson RE; Munger MA; Weintraub WS; LaFleur J
Am J Cardiol; 2018 Dec; 122(11):1809-1816. PubMed ID: 30292334
[TBL] [Abstract][Full Text] [Related]
16. Ranolazine Reduces Angina in Women with Ischemic Heart Disease: Results of an Open-Label, Multicenter Trial.
Mehta PK; Sharma S; Minissian M; Harsch MR; Martinson M; Nyman JA; Shaw LJ; Bairey Merz CN; Wenger NK
J Womens Health (Larchmt); 2019 May; 28(5):573-582. PubMed ID: 30888919
[No Abstract] [Full Text] [Related]
17. Effects of the Antianginal Drugs Ranolazine, Nicorandil, and Ivabradine on Coronary Microvascular Function in Patients With Nonobstructive Coronary Artery Disease: A Meta-analysis of Randomized Controlled Trials.
Zhu H; Xu X; Fang X; Zheng J; Zhao Q; Chen T; Huang J
Clin Ther; 2019 Oct; 41(10):2137-2152.e12. PubMed ID: 31548105
[TBL] [Abstract][Full Text] [Related]
18. The Impact of De-escalation of Antianginal Medications on Health Status After Percutaneous Coronary Intervention.
Qintar M; Towheed A; Tang F; Salisbury AC; Ho PM; Grantham JA; Spertus JA; Arnold SV
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29054844
[TBL] [Abstract][Full Text] [Related]
19. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes.
Timmis AD; Chaitman BR; Crager M
Eur Heart J; 2006 Jan; 27(1):42-8. PubMed ID: 16176940
[TBL] [Abstract][Full Text] [Related]
20. De-escalation of antianginal medications after successful chronic total occlusion percutaneous coronary intervention: Frequency and relationship with health status.
Qintar M; Hirai T; Arnold SV; Sheehy J; Sapontis J; Jones P; Tang Y; Lombardi W; Karmpaliotis D; Moses J; Patterson C; Nicholson WJ; Cohen DJ; Spertus JA; Grantham JA; Salisbury AC
Am Heart J; 2019 Aug; 214():1-8. PubMed ID: 31152872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
